{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:19Z","timestamp":1792783099648,"version":"4.5.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"General Projects of Education Department of Liaoning Province","award":["LJ212410140038"],"award-info":[{"award-number":["LJ212410140038"]}],"id":[{"id":"https:\/\/ror.org\/0022v2454","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Shenyang Natural Science Foundation of Key Laboratory","award":["23-503-6-12"],"award-info":[{"award-number":["23-503-6-12"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-025-11379-0","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:57:39Z","timestamp":1760612259000},"page":"6589-6613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent advances in Pyrazolo[3,4-d]pyrimidine-based dual inhibitors in the treatment of cancers"],"prefix":"10.1007","volume":"30","author":[{"given":"Hanrui","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruosong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"13","key":"11379_CR1","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.3390\/cancers14133158","volume":"14","author":"J Haier","year":"2022","unstructured":"Haier J, Schaefers J (2022) Economic perspective of cancer care and its consequences for vulnerable groups. Cancers (Basel) 14(13):3158. https:\/\/doi.org\/10.3390\/cancers14133158","journal-title":"Cancers (Basel)"},{"issue":"2","key":"11379_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3322\/caac.21443","volume":"68","author":"PM Carrera","year":"2018","unstructured":"Carrera PM, Kantarjian HM, Blinder VS (2018) The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. A Cancer J Clin 68(2):153\u2013165. https:\/\/doi.org\/10.3322\/caac.21443","journal-title":"A Cancer J Clin"},{"key":"11379_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.dhjo.2025.101851","author":"Y Yang","year":"2025","unstructured":"Yang Y et al (2025) Cancer inequalities experienced by people with disability: a systematic review. Disabil Health J. https:\/\/doi.org\/10.1016\/j.dhjo.2025.101851","journal-title":"Disabil Health J"},{"issue":"1","key":"11379_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(24)00522-9","volume":"26","author":"R Casolino","year":"2025","unstructured":"Casolino R et al (2025) Integrating cancer into crisis: a global vision for action from WHO and partners. Lancet Oncol 26(1):55\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(24)00522-9","journal-title":"Lancet Oncol"},{"key":"11379_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107413","volume":"147","author":"OA Hamed","year":"2024","unstructured":"Hamed OA et al (2024) Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity. Bioorg Chem 147:107413. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107413","journal-title":"Bioorg Chem"},{"key":"11379_CR6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.procbio.2023.07.018","volume":"132","author":"KT Jha","year":"2023","unstructured":"Jha KT et al (2023) Medicinal perspectives and structure-activity relationship studies of pyrimidine based Bruton\u2019s tyrosine kinase inhibitors as potential anticancer agents. Process Biochem 132:308\u2013322. https:\/\/doi.org\/10.1016\/j.procbio.2023.07.018","journal-title":"Process Biochem"},{"key":"11379_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2025.102804","volume":"96","author":"F Stracci","year":"2025","unstructured":"Stracci F et al (2025) Challenges of cancer registration and epidemiology in Italy. Cancer Epidemiol 96:102804. https:\/\/doi.org\/10.1016\/j.canep.2025.102804","journal-title":"Cancer Epidemiol"},{"key":"11379_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.semcancer.2025.05.009","volume":"113","author":"C Zeng","year":"2025","unstructured":"Zeng C et al (2025) Metabolic reprogramming in cancer therapy-related cardiovascular toxicity: mechanisms and intervention strategies. Semin Cancer Biol 113:39\u201358. https:\/\/doi.org\/10.1016\/j.semcancer.2025.05.009","journal-title":"Semin Cancer Biol"},{"key":"11379_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jics.2025.101763","volume":"102","author":"AS Abdelkhalek","year":"2025","unstructured":"Abdelkhalek AS et al (2025) An overview of pyrazolo[3,4-d]pyrimidine heterocycles: recent synthetic approaches and biological activities. J Indian Chem Soc 102:101763. https:\/\/doi.org\/10.1016\/j.jics.2025.101763","journal-title":"J Indian Chem Soc"},{"key":"11379_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103901","volume":"101","author":"D Kim","year":"2020","unstructured":"Kim D et al (2020) Development of pyrazolo[3,4-d]pyrimidine-6-amine-based TRAP1 inhibitors that demonstrate in vivo anticancer activity in mouse xenograft models. Bioorg Chem 101:103901. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103901","journal-title":"Bioorg Chem"},{"key":"11379_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.140352","volume":"1322","author":"EM Radwan","year":"2025","unstructured":"Radwan EM et al (2025) Synthesis, characterization and anticancer investigation of some novel 2,5-disubstituted-1,3-thiazol-4-(5H)-ones and 1-substituted-1H-pyrazolo [3,4-d] thiazole derivatives. J Mol Struct 1322:140352. https:\/\/doi.org\/10.1016\/j.molstruc.2024.140352","journal-title":"J Mol Struct"},{"key":"11379_CR12","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1096\/fj.07-9873com","volume":"22","author":"A Spreafico","year":"2008","unstructured":"Spreafico A et al (2008) Antiproliferative and proapoptotic activities of new pyrazolo [3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. FASEB J 22:1560. https:\/\/doi.org\/10.1096\/fj.07-9873com","journal-title":"FASEB J"},{"key":"11379_CR13","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1021\/jm050603r","volume":"49","author":"F Carraro","year":"2006","unstructured":"Carraro F et al (2006) Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J Med Chem 49:1549. https:\/\/doi.org\/10.1021\/jm050603r","journal-title":"J Med Chem"},{"key":"11379_CR14","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1021\/jm701240c","volume":"51","author":"F Manetti","year":"2008","unstructured":"Manetti F et al (2008) Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem 51:1252. https:\/\/doi.org\/10.1021\/jm701240c","journal-title":"J Med Chem"},{"key":"11379_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.923260","volume":"12","author":"ZC Zhang","year":"2022","unstructured":"Zhang ZC, Li D, Yun H, Tong J, Liu W, Chai KQ et al (2022) Opportunities and challenges of targeting c-Met in the treatment of digestive tumors. J Front Oncol 12:923260. https:\/\/doi.org\/10.3389\/fonc.2022.923260","journal-title":"J Front Oncol"},{"key":"11379_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116477","volume":"272","author":"F Jin","year":"2024","unstructured":"Jin F et al (2024) Recent advances in c-Met-based dual inhibitors in the treatment of cancers. Eur J Med Chem 272:116477. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116477","journal-title":"Eur J Med Chem"},{"key":"11379_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2025.118160","volume":"123","author":"M Muddassar","year":"2025","unstructured":"Muddassar M et al (2025) Computational identification and experimental characterization of an aurora kinase inhibitor. Bioorg Med Chem 123:118160. https:\/\/doi.org\/10.1016\/j.bmc.2025.118160","journal-title":"Bioorg Med Chem"},{"key":"11379_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.130913","volume":"265","author":"D Gupta","year":"2024","unstructured":"Gupta D et al (2024) A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics. Int J Biol Macromol 265:130913. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.130913","journal-title":"Int J Biol Macromol"},{"key":"11379_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107976","author":"G Teli","year":"2025","unstructured":"Teli G et al (2025) Recent advancements in mechanistic research, therapeutic potential, and structure-activity relationships of aurora kinase inhibitors in cancer therapies. Bioorg Chem. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107976","journal-title":"Bioorg Chem"},{"key":"11379_CR20","doi-asserted-by":"publisher","first-page":"6869","DOI":"10.1158\/1078-0432.CCR-06-1405","volume":"12","author":"RD Carvajal","year":"2006","unstructured":"Carvajal RD, Tse A, Schwartz GK (2006) Aurora kinases: new targets for cancer therapy, Clinical cancer research: an official journal of the American Association for. Can Res 12:6869\u20136875. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1405","journal-title":"Can Res"},{"key":"11379_CR21","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1038\/s41388-021-01766-w","volume":"40","author":"FD Naso","year":"2021","unstructured":"Naso FD, Boi D, Ascanelli C, Pamfil G, Lindon C, Paiardini A, Guarguaglini G (2021) Nuclear localisation of Aurora-A: its regulation and significance for Aurora-A functions in cancer. Oncogene 40:3917\u20133928. https:\/\/doi.org\/10.1038\/s41388-021-01766-w","journal-title":"Oncogene"},{"key":"11379_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ceb.2008.12.005","volume":"21","author":"JB Moseley","year":"2009","unstructured":"Moseley JB, Nurse P (2009) Cdk1 and cell morphology: connections and directions. Curr Opin Cell Biol 21:82\u201388. https:\/\/doi.org\/10.1016\/j.ceb.2008.12.005","journal-title":"Curr Opin Cell Biol"},{"key":"11379_CR23","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1182\/blood-2019-123287","volume":"134","author":"GE R\u00f8dland","year":"2019","unstructured":"R\u00f8dland GE, Melhus K, Generalov R, Gilani S, Bertoni F, Dahle J, Sylju\u00e5sen R, Patzke S (2019) The dual cell cycle kinase inhibitor JNJ-7706621 reverses resistance to CD37 targeted radioimmunotherapy in activated B cell like diffuse large B cell lymphoma cell lines. Blood 134:2574. https:\/\/doi.org\/10.1182\/blood-2019-123287","journal-title":"Blood"},{"key":"11379_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114126","volume":"158","author":"S Sriramulu","year":"2023","unstructured":"Sriramulu S, Thoidingjam S, Brown SL, Siddiqui F, Movsas B, Nyati S (2023) Molecular targets that sensitize cancer to radiation killing: from the bench to the bedside. Biomed Pharmacother 158:114126. https:\/\/doi.org\/10.1016\/j.biopha.2022.114126","journal-title":"Biomed Pharmacother"},{"key":"11379_CR25","doi-asserted-by":"publisher","first-page":"9038","DOI":"10.1158\/0008-5472.CAN-05-0882","volume":"65","author":"S Emanuel","year":"2005","unstructured":"Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ, Wetter SK, Hollister B, Kruger WW, Napier C, Jolliffe L, Middleton SA (2005) The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res 65:9038\u20139046. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0882","journal-title":"Cancer Res"},{"key":"11379_CR26","doi-asserted-by":"publisher","unstructured":"Le Brazidec JY et al (2012) Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo [3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1. Bioorg Med Chem Lett 22:2070\u20132074, https:\/\/doi.org\/10.1016\/j.bmcl.2012.01.019","DOI":"10.1016\/j.bmcl.2012.01.019"},{"key":"11379_CR27","doi-asserted-by":"publisher","first-page":"42419","DOI":"10.1074\/jbc.C200426200","volume":"277","author":"GMT Cheetham","year":"2002","unstructured":"Cheetham GMT, Knegtel RMA, Coll JT, Renwick SB, Swenson L, Weber P, Lippke JA, Austen DA (2002) Crystal structure of aurora-2, an oncogenic serine\/threonine kinase. J Biol Chem 277:42419\u201342422. https:\/\/doi.org\/10.1074\/jbc.C200426200","journal-title":"J Biol Chem"},{"key":"11379_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116696","volume":"276","author":"Z Huang","year":"2024","unstructured":"Huang Z et al (2024) Overview of class I HDAC modulators: inhibitors and degraders. Eur J Med Chem 276:116696. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116696","journal-title":"Eur J Med Chem"},{"key":"11379_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad073.194","author":"V Marquardt","year":"2023","unstructured":"Marquardt V et al (2023) a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB TGM2 driven tumor inflammation. J Immunother Cancer. https:\/\/doi.org\/10.1093\/neuonc\/noad073.194","journal-title":"J Immunother Cancer"},{"key":"11379_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105594","volume":"156","author":"E Baglini","year":"2021","unstructured":"Baglini E et al (2021) Multiple topoisomerase I (Topo I), topoisomerase II (Topo II) and tyrosyl- DNA phosphodiesterase (TDP) inhibitors in the development of anticancer drugs. Eur J Pharm Sci 156:105594. https:\/\/doi.org\/10.1016\/j.ejps.2020.105594","journal-title":"Eur J Pharm Sci"},{"key":"11379_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117611","volume":"291","author":"A Acharya","year":"2025","unstructured":"Acharya A et al (2025) Topoisomerase II-targeting anticancer clinical candidates and drugs: a critical analysis, unravelling molecular medicinal insights and promising research roadmap. Eur J Med Chem 291:117611. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117611","journal-title":"Eur J Med Chem"},{"key":"11379_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106548","volume":"136","author":"HK Swedan","year":"2023","unstructured":"Swedan HK et al (2023) Topoisomerase II inhibitors design: early studies and new perspectives. Bioorg Chem 136:106548. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106548","journal-title":"Bioorg Chem"},{"issue":"11","key":"11379_CR33","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1158\/1535-7163.MCT-09-0254","volume":"8","author":"F Bruzzese","year":"2009","unstructured":"Bruzzese F, Rocco M, Castelli S, Gennaro ED, Desideri A, Budillon A (2009) Syn- ergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 8(11):3075\u20133087. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0254","journal-title":"Mol Cancer Ther"},{"key":"11379_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103833","volume":"99","author":"LL He","year":"2020","unstructured":"He LL, Qi Q, Wang X, Li Y, Zhu Y, Wang XF, Xu L (2020) Synthesis of two novel pyrazolo [1,5- a ]pyrimidine compounds with antibacterial activity and biophys- ical insights into their interactions with plasma protein. Bio Chem 99:103833. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103833","journal-title":"Bio Chem"},{"key":"11379_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.134221","volume":"1272","author":"J Dong","year":"2023","unstructured":"Dong J, Zhu X, Yu W et al (2023) Pyrazolo [3,4- d ]pyrimidine-based dual HDAC\/Topo II inhibitors: design, synthesis, and biological evaluation as potential antitumor agents. J Mol Struct 1272:134221. https:\/\/doi.org\/10.1016\/j.molstruc.2022.134221","journal-title":"J Mol Struct"},{"key":"11379_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103748","volume":"98","author":"YL Tang","year":"2020","unstructured":"Tang YL, Zheng X, Qi Y, Pu XJ, Mao ZW (2020) Synthesis and anti-inflammatory evaluation of new chalcone derivatives bearing bispiperazine linker as IL-1 \u03b2 inhibitors. Bio Chem 98:103748. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103748","journal-title":"Bio Chem"},{"issue":"2","key":"11379_CR37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cmdc.201402459","volume":"10","author":"B Pogorelcnik","year":"2015","unstructured":"Pogorelcnik B, Brvar M, Zegura B et al (2015) Discovery of mono- and disubstituted 1H-pyrazolo [3,4]pyrimidines and 9H-purines as catalytic inhibitors of human DNA topoisomerase II \u03b1. Chem Med Chem 10(2):345\u2013359. https:\/\/doi.org\/10.1002\/cmdc.201402459","journal-title":"Chem Med Chem"},{"key":"11379_CR38","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ejmech.2019.04.055","volume":"175","author":"K Bergant","year":"2019","unstructured":"Bergant K, Jane\u017ei\u010d M, Valjavec K, Sosi\u010d I, Pajk S, \u0160tampar M, \u017degura B, Gobec S, Filipi\u010d M, Perdih A (2019) Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase II\u03b1. Eur J Med Chem 175:330\u2013348. https:\/\/doi.org\/10.1016\/j.ejmech.2019.04.055","journal-title":"Eur J Med Chem"},{"key":"11379_CR39","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/med.10041","volume":"23","author":"I Muegge","year":"2003","unstructured":"Muegge I (2003) Selection criteria for drug-like compounds. Med Res Rev 23:302\u2013321. https:\/\/doi.org\/10.1002\/med.10041","journal-title":"Med Res Rev"},{"key":"11379_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.151970","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Xie L, Liu B, Deng Y, Li P, Dai Y, Liu J, Yi C (2025) Novel insight into the role of Src family kinases in hepatocellular carcinoma and therapeutic potential. Biochem Biophys Res Commun. https:\/\/doi.org\/10.1016\/j.bbrc.2025.151970","journal-title":"Biochem Biophys Res Commun"},{"key":"11379_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106934","volume":"142","author":"X-W Dang","year":"2024","unstructured":"Dang X-W et al (2024) Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities. Bioorg Chem 142:106934. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106934","journal-title":"Bioorg Chem"},{"issue":"4","key":"11379_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0959-440X(02)00383-4","volume":"94","author":"R Roskoski Jr","year":"2015","unstructured":"Roskoski R Jr (2015) Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res 94(4):9\u201325. https:\/\/doi.org\/10.1016\/S0959-440X(02)00383-4","journal-title":"Pharmacol Res"},{"key":"11379_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117369","volume":"287","author":"Y Su","year":"2025","unstructured":"Su Y et al (2025) Advancing Src kinase inhibition: from structural design to therapeutic innovation\u2014a comprehensive review. Eur J Med Chem 287:117369. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117369","journal-title":"Eur J Med Chem"},{"issue":"4","key":"11379_CR44","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1023\/A:1023772912750","volume":"22","author":"JM Summy","year":"2003","unstructured":"Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22(4):337\u2013358. https:\/\/doi.org\/10.1023\/A:1023772912750","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"11379_CR45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00665949","volume":"33","author":"AE Ottenhoff-Kalff","year":"1995","unstructured":"Ottenhoff-Kalff AE, Van Oirschot BA, Hennipman A et al (1995) Protein tyrosine phosphatase activity as a diagnostic parameter in breast cancer. Breast Cancer Res Treat 33(3):245\u2013256. https:\/\/doi.org\/10.1007\/BF00665949","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"11379_CR46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40164-023-00463-6","volume":"12","author":"J Cicero","year":"2023","unstructured":"Cicero J, Trouvilliez S, Palma M et al (2023) ProNGF promotes brain metastasis through TrkA\/EphA2 induced Src activation in triple negative breast cancer cells. Exp Hematol Oncol 12(1):104. https:\/\/doi.org\/10.1186\/s40164-023-00463-6","journal-title":"Exp Hematol Oncol"},{"key":"11379_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2013.00416","volume":"4","author":"ST Liu","year":"2014","unstructured":"Liu ST, Pham H, Pandol SJ et al (2014) Src as the link between inflammation and cancer. Front Physiol 4:416. https:\/\/doi.org\/10.3389\/fphys.2013.00416","journal-title":"Front Physiol"},{"issue":"12","key":"11379_CR48","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167270","volume":"8","author":"W Dunker","year":"2023","unstructured":"Dunker W, Zaver SA, Pineda JMB et al (2023) The proto-oncogene SRC phosphorylates cGAS to inhibit an antitumor immune response. JCI Insight 8(12):167270. https:\/\/doi.org\/10.1172\/jci.insight.167270","journal-title":"JCI Insight"},{"issue":"3","key":"11379_CR49","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ijrobp.2022.09.060","volume":"115","author":"YS Weng","year":"2023","unstructured":"Weng YS, Chiang IT, Tsai JJ et al (2023) Lenvatinib synergistically promotes radiation therapy in hepatocellular carcinoma by inhibiting Src\/STAT3\/NF-\u03baB-mediated epithelial-mesenchymal transition and metastasis. Int J Radiat Oncol Biol Phys 115(3):719\u2013732. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.060","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"11379_CR50","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/bjc.2014.327","volume":"111","author":"G Peir\u00f3","year":"2014","unstructured":"Peir\u00f3 G, Ortiz-Mart\u00ednez F, Gallardo A et al (2014) Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. Br J Cancer 111(4):689\u2013695. https:\/\/doi.org\/10.1038\/bjc.2014.327","journal-title":"Br J Cancer"},{"issue":"6","key":"11379_CR51","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3892\/ol.2023.14116","volume":"26","author":"M Takahashi","year":"2023","unstructured":"Takahashi M, Araki T, Yashima H et al (2023) Increased c-SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma. Oncol Lett 26(6):529. https:\/\/doi.org\/10.3892\/ol.2023.14116","journal-title":"Oncol Lett"},{"issue":"4","key":"11379_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100668","volume":"5","author":"T Tozuka","year":"2024","unstructured":"Tozuka T, Noro R, Yoshida K et al (2024) Phosphoproteomic analysis identified mutual phosphorylation of FAK and Src as a mechanism of osimertinib resistance in EGFR-mutant lung cancer. JTO Clin Res Rep 5(4):100668. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100668","journal-title":"JTO Clin Res Rep"},{"issue":"10","key":"11379_CR53","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41573-021-00303-4","volume":"20","author":"MM Attwood","year":"2021","unstructured":"Attwood MM, Fabbro D, Sokolov AV et al (2021) Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov 20(10):798. https:\/\/doi.org\/10.1038\/s41573-021-00303-4","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"11379_CR54","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville R, Buchdunger E, Zimmermann J et al (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1(7):493\u2013502. https:\/\/doi.org\/10.1038\/nrd839","journal-title":"Nat Rev Drug Discov"},{"key":"11379_CR55","doi-asserted-by":"publisher","first-page":"8955","DOI":"10.1021\/jm400856t","volume":"56","author":"J-U Peters","year":"2013","unstructured":"Peters J-U (2013) Polypharmacology-foe or friend? J Med Chem 56:8955\u20138971. https:\/\/doi.org\/10.1021\/jm400856t","journal-title":"J Med Chem"},{"key":"11379_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2025.05.001","author":"T Shammas","year":"2025","unstructured":"Shammas T et al (2025) BCR-ABL: the molecular mastermind behind chronic myeloid leukemia. Cytokine Growth Factor Rev. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.05.001","journal-title":"Cytokine Growth Factor Rev"},{"issue":"12","key":"11379_CR57","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1096\/fj.09-138412","volume":"23","author":"TM Allington","year":"2009","unstructured":"Allington TM, Galliher-Beckley AJ, Schiemann WP (2009) Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. FASEB J 23(12):4231\u20134243. https:\/\/doi.org\/10.1096\/fj.09-138412","journal-title":"FASEB J"},{"issue":"10","key":"11379_CR58","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M et al (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5(10):835\u2013844. https:\/\/doi.org\/10.1038\/nrd2130","journal-title":"Nat Rev Drug Discov"},{"key":"11379_CR59","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","volume":"18","author":"JV Melo","year":"2004","unstructured":"Melo JV, Deininger MW (2004) Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. Hematol\/oncol Clin 18:545\u2013568. https:\/\/doi.org\/10.1016\/j.hoc.2004.03.008","journal-title":"Hematol\/oncol Clin"},{"key":"11379_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106678","volume":"193","author":"L Sun","year":"2024","unstructured":"Sun L et al (2024) Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies. Eur J Pharm Sci 193:106678. https:\/\/doi.org\/10.1016\/j.ejps.2023.106678","journal-title":"Eur J Pharm Sci"},{"key":"11379_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnves.2025.100017","volume":"1","author":"K Qiu","year":"2025","unstructured":"Qiu K, Wang X, Liu Z et al (2025) Targeting USP10\u2013FAK pathway sensitizes BCR-ABL+ leukemia cells to tyrosine kinase inhibitors. Cell Invest 1:100017. https:\/\/doi.org\/10.1016\/j.clnves.2025.100017","journal-title":"Cell Invest"},{"key":"11379_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108189","volume":"156","author":"Z Qian","year":"2025","unstructured":"Qian Z et al (2025) The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia. Bioorg Chem 156:108189. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108189","journal-title":"Bioorg Chem"},{"key":"11379_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2025.106100","volume":"235","author":"MG Martina","year":"2025","unstructured":"Martina MG et al (2025) Targeting PI4KB and Src\/Abl host kinases as broad-spectrum antiviral strategy: Myth or real opportunity? Antivir Res 235:106100. https:\/\/doi.org\/10.1016\/j.antiviral.2025.106100","journal-title":"Antivir Res"},{"key":"11379_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2025.130105","volume":"119","author":"C Lin","year":"2025","unstructured":"Lin C et al (2025) Disrupted target binding with acryloyl group as potential Bcr-Abl\/C-Src dual kinase inhibitor optimization strategies with maintained antitumor activity. Bioorg Med Chem Lett 119:130105. https:\/\/doi.org\/10.1016\/j.bmcl.2025.130105","journal-title":"Bioorg Med Chem Lett"},{"key":"11379_CR65","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2133\/dmpk.DMPK-13-RG-094","volume":"29","author":"C Zamperini","year":"2014","unstructured":"Zamperini C et al (2014) CYP-dependent metabolism of antitumor pyrazolo[3,4-d]pyrimidine derivatives is characterized by an oxidative dechlorination reaction. Drug Metab Pharmacokinet 29:433\u2013440. https:\/\/doi.org\/10.2133\/dmpk.DMPK-13-RG-094","journal-title":"Drug Metab Pharmacokinet"},{"key":"11379_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.106071","volume":"128","author":"S Di Maria","year":"2022","unstructured":"Di Maria S et al (2022) Novel pyrazolo[3,4-d]pyrimidines as dual Src\/Bcr-Abl kinase inhibitors: synthesis and biological evaluation for chronic myeloid leukemia treatment. Bioorg Chem 128:106071. https:\/\/doi.org\/10.1016\/j.bioorg.2022.106071","journal-title":"Bioorg Chem"},{"key":"11379_CR67","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","volume":"65","author":"CC Ayala-Aguilera","year":"2022","unstructured":"Ayala-Aguilera CC et al (2022) Small molecule kinase inhibitor drugs (1995\u20132021): medical indication, pharmacology, and synthesis. J Med Chem 65:1047\u20131131. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00963","journal-title":"J Med Chem"},{"key":"11379_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.138741","volume":"1313","author":"AF Kassem","year":"2024","unstructured":"Kassem AF et al (2024) Pyridine-based glycosides bearing 1,2,4-triazole and their 1,3,4-oxadiazole analogues as potential EGFR and CDK-2 inhibitors: design, synthesis, antiproliferative activity and in silico studies. J Mol Struct 1313:138741. https:\/\/doi.org\/10.1016\/j.molstruc.2024.138741","journal-title":"J Mol Struct"},{"key":"11379_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2024.108134","volume":"112","author":"BK Chagaleti","year":"2024","unstructured":"Chagaleti BK et al (2024) Targeting cyclin-dependent kinase 2 CDK2: insights from molecular docking and dynamics simulation\u2014a systematic computational approach to discover novel cancer therapeutics. Comput Biol Chem 112:108134. https:\/\/doi.org\/10.1016\/j.compbiolchem.2024.108134","journal-title":"Comput Biol Chem"},{"key":"11379_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117503","volume":"13","author":"W Chen","year":"2025","unstructured":"Chen W et al (2025) Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer. Eur J Med Chem 13:117503. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117503","journal-title":"Eur J Med Chem"},{"key":"11379_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2025.130166","volume":"122","author":"Y Zhang","year":"2025","unstructured":"Zhang Y et al (2025) Development of 9H-purine scaffold as novel CDK2 inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem Lett 122:130166. https:\/\/doi.org\/10.1016\/j.bmcl.2025.130166","journal-title":"Bioorg Med Chem Lett"},{"key":"11379_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.06.182","author":"T Yap","year":"2023","unstructured":"Yap T et al (2023) VELA: a first-in-human phase 1\/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4\/6 inhibitor (CDK4\/6i)-resistant advanced solid tumors (1275). Gynecol Oncol. https:\/\/doi.org\/10.1016\/j.ygyno.2023.06.182","journal-title":"Gynecol Oncol"},{"issue":"3","key":"11379_CR73","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","volume":"14","author":"C Dietrich","year":"2024","unstructured":"Dietrich C et al (2024) INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov 14(3):446\u2013467. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0954","journal-title":"Cancer Discov"},{"key":"11379_CR74","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S1875-5364(25)60846-6","volume":"23","author":"W Chen","year":"2025","unstructured":"Chen W et al (2025) Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment. Chin J Nat Med 23:286\u2013298. https:\/\/doi.org\/10.1016\/S1875-5364(25)60846-6","journal-title":"Chin J Nat Med"},{"key":"11379_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104324","volume":"196","author":"R Gerosa","year":"2024","unstructured":"Gerosa R et al (2024) Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions. Crit Rev Oncol Hematol 196:104324. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104324","journal-title":"Crit Rev Oncol Hematol"},{"key":"11379_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122840","volume":"351","author":"MO Ayaz","year":"2024","unstructured":"Ayaz MO et al (2024) Identification of a novel GSK3\u03b2 inhibitor involved in abrogating KRas dependent pancreatic tumors in Wnt\/beta-catenin and NF-kB dependent manner. Life Sci 351:122840. https:\/\/doi.org\/10.1016\/j.lfs.2024.122840","journal-title":"Life Sci"},{"key":"11379_CR77","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4209475","author":"T Jaworski","year":"2019","unstructured":"Jaworski T, Banach-Kasper E, Gralec K (2019) GSK-3\u03b2 at the intersection of neuronal plasticity and neurodegeneration. Neural Plast. https:\/\/doi.org\/10.1155\/2019\/4209475","journal-title":"Neural Plast"},{"key":"11379_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114145","volume":"207","author":"AD Pearson","year":"2024","unstructured":"Pearson AD et al (2024) Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3\u03b2 inhibitors in children and adolescents with cancer. Eur J Cancer 207:114145. https:\/\/doi.org\/10.1016\/j.ejca.2024.114145","journal-title":"Eur J Cancer"},{"key":"11379_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100779","volume":"58","author":"C Pecoraro","year":"2021","unstructured":"Pecoraro C et al (2021) GSK3\u03b2 as a novel promising target to overcome chemoresistance in pancreatic cancer. Drug Resist Updates 58:100779. https:\/\/doi.org\/10.1016\/j.drup.2021.100779","journal-title":"Drug Resist Updates"},{"key":"11379_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189324","volume":"1880","author":"Z Sabeel","year":"2025","unstructured":"Sabeel Z et al (2025) The duality of GSK-3\u03b2 in urinary bladder cancer: tumor suppressor and promoter roles through multiple signaling pathways. Biochimica et Biophysica Acta (BBA)-Rev Cancer 1880:189324. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189324","journal-title":"Biochimica et Biophysica Acta (BBA)-Rev Cancer"},{"key":"11379_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107566","volume":"150","author":"MTM Nemr","year":"2024","unstructured":"Nemr MTM et al (2024) Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2\/GSK3\u03b2 kinase inhibitors; molecular docking study, and ADME prediction. Bioorg Chem 150:107566. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107566","journal-title":"Bioorg Chem"},{"key":"11379_CR82","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.biopha.2018.08.116","volume":"107","author":"TA Chohan","year":"2018","unstructured":"Chohan TA et al (2018) An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers. Biomed Pharmacother 107:1326\u20131341. https:\/\/doi.org\/10.1016\/j.biopha.2018.08.116","journal-title":"Biomed Pharmacother"},{"key":"11379_CR83","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejmech.2014.08.049","volume":"86","author":"P Zhao","year":"2014","unstructured":"Zhao P et al (2014) Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)\/glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) phosphorylation inhibitors. Eur J Med Chem 86:165\u2013174. https:\/\/doi.org\/10.1016\/j.ejmech.2014.08.049","journal-title":"Eur J Med Chem"},{"key":"11379_CR84","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ejmech.2018.12.073","volume":"164","author":"M Xu","year":"2019","unstructured":"Xu M et al (2019) Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3\u03b2 inhibitors: a critical review. Eur J Med Chem 164:448\u2013470. https:\/\/doi.org\/10.1016\/j.ejmech.2018.12.073","journal-title":"Eur J Med Chem"},{"key":"11379_CR85","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s11224-018-1224-z","volume":"30","author":"L Pacureanu","year":"2019","unstructured":"Pacureanu L et al (2019) Portraying the selectivity of GSK-3 inhibitors towards CDK-2 by 3D similarity and molecular docking. Struct Chem 30:911\u2013923. https:\/\/doi.org\/10.1007\/s11224-018-1224-z","journal-title":"Struct Chem"},{"key":"11379_CR86","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.bmc.2019.03.028","volume":"27","author":"NA Lozinskaya","year":"2019","unstructured":"Lozinskaya NA et al (2019) Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3\u03b2 inhibitors. Bioorg Med Chem 27:1804\u20131817. https:\/\/doi.org\/10.1016\/j.bmc.2019.03.028","journal-title":"Bioorg Med Chem"},{"key":"11379_CR87","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949\u2013954. https:\/\/doi.org\/10.1038\/nature00766","journal-title":"Nature"},{"key":"11379_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102905","volume":"134","author":"S Napolitano","year":"2025","unstructured":"Napolitano S et al (2025) BRAFV600E mutant metastatic colorectal cancer: current advances in personalized treatment and future perspectives. Cancer Treat Rev 134:102905. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102905","journal-title":"Cancer Treat Rev"},{"key":"11379_CR89","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jconrel.2024.09.034","volume":"375","author":"J Wang","year":"2024","unstructured":"Wang J et al (2024) Confined copper depletion via a hydrogel platform for reversing dabrafenib\/cetuximab resistance in BRAFV600E-mutant colorectal cancer. J Control Release 375:643\u2013653. https:\/\/doi.org\/10.1016\/j.jconrel.2024.09.034","journal-title":"J Control Release"},{"key":"11379_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2025.114440","author":"J Bharti","year":"2025","unstructured":"Bharti J et al (2025) BRAF V600E in cancer: exploring structural complexities, mutation profiles, and pathway dysregulation. Exp Cell Res. https:\/\/doi.org\/10.1016\/j.yexcr.2025.114440","journal-title":"Exp Cell Res"},{"key":"11379_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177299","author":"W Feng","year":"2025","unstructured":"Feng W et al (2025) Association of VEGFR2 polymorphisms with clinical outcomes of anti-angiogenesis therapy in cancer patients: a systematic review and meta-analysis. Eur J Pharmacol. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177299","journal-title":"Eur J Pharmacol"},{"key":"11379_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/genes13091535","author":"Y Chen","year":"2022","unstructured":"Chen Y et al (2022) PROZ associated with Sorafenib sensitivity may serve as a potential target to enhance the efficacy of combined immunotherapy for hepatocellular carcinoma. Genes. https:\/\/doi.org\/10.3390\/genes13091535","journal-title":"Genes"},{"key":"11379_CR93","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s12072-023-10519-8","volume":"17","author":"X Duan","year":"2023","unstructured":"Duan X et al (2023) Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study. Hepatol Int 17:915\u2013926. https:\/\/doi.org\/10.1007\/s12072-023-10519-8","journal-title":"Hepatol Int"},{"key":"11379_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22040542","author":"Y Fu","year":"2017","unstructured":"Fu Y, Wang YY, Wan SH, Li ZH, Wang GF, Zhang JJ, Wu XY (2017) Bisarylureas based on 1H-pyrazolo[3,4-d]pyrimidine scaffold as novel pan-RAF inhibitors with potent anti-proliferative activities: structure-based design, synthesis, biological evaluation and molecular modelling studies. Molecules. https:\/\/doi.org\/10.3390\/molecules22040542","journal-title":"Molecules"},{"key":"11379_CR95","unstructured":"Wang. Design, Synthesis, Biological Evaluation, and Molecular Modeling of Novel Lipo-Pyrazolo[3,4-d]pyrimidine Derivatives as BRAF V600E and VEGFR-2 Dual Inhibitors. Guangdong, Guangzhou"},{"key":"11379_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2025.118244","author":"WI Elsisi","year":"2025","unstructured":"Elsisi WI et al (2025) Recent achievements in molecular insights, anticancer activities, and comparative structure activity relationships of thiazolidin-4-one derivatives as EGFR inhibitors (2019-present). Bioorg Med Chem. https:\/\/doi.org\/10.1016\/j.bmc.2025.118244","journal-title":"Bioorg Med Chem"},{"key":"11379_CR97","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1128\/MMBR.00013-12","volume":"76","author":"M Cargnello","year":"2012","unstructured":"Cargnello M, Roux PP (2012) Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases (vol 75, pg 50, 2011). Microbiol Mol Biol Rev 76:496\u2013496. https:\/\/doi.org\/10.1128\/MMBR.00013-12","journal-title":"Microbiol Mol Biol Rev"},{"key":"11379_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108494","volume":"202","author":"M Torasawa","year":"2025","unstructured":"Torasawa M et al (2025) Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma. Lung Cancer 202:108494. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108494","journal-title":"Lung Cancer"},{"key":"11379_CR99","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.jds.2023.01.035","volume":"18","author":"H Lu","year":"2023","unstructured":"Lu H et al (2023) Mucin 1 promotes salivary gland cancer cell proliferation and metastasis by regulating the epidermal growth factor receptor signaling pathway. J Dent Sci 18:1651\u20131662. https:\/\/doi.org\/10.1016\/j.jds.2023.01.035","journal-title":"J Dent Sci"},{"key":"11379_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.oor.2024.100592","volume":"11","author":"VP Veeraraghavan","year":"2024","unstructured":"Veeraraghavan VP et al (2024) Emerging targeted therapies in oral oncology: focus on EGFR inhibition. Oral Oncol Rep 11:100592. https:\/\/doi.org\/10.1016\/j.oor.2024.100592","journal-title":"Oral Oncol Rep"},{"key":"11379_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101260","volume":"53","author":"Q Zhou","year":"2024","unstructured":"Zhou Q et al (2024) Consensus on the lung cancer management after third-generation EGFR-TKI resistance. Lancet Reg Health Western Pac 53:101260. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101260","journal-title":"Lancet Reg Health Western Pac"},{"key":"11379_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189194","volume":"1879","author":"F Teng","year":"2024","unstructured":"Teng F et al (2024) Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: unexpected potential benefits. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1879:189194. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189194","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"11379_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2025.111138","volume":"135","author":"MA Habibi","year":"2025","unstructured":"Habibi MA et al (2025) The safety and efficacy of tyrosine kinase inhibitors against EGFR in patients with glioma; a systematic review, meta-analysis, and sub-group analysis on glioblastoma. J Clin Neurosci 135:111138. https:\/\/doi.org\/10.1016\/j.jocn.2025.111138","journal-title":"J Clin Neurosci"},{"key":"11379_CR104","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S2468-1253(23)00479-X","volume":"9","author":"S Napolitano","year":"2024","unstructured":"Napolitano S et al (2024) Targeting the EGFR signalling pathway in metastatic colorectal cancer. Lancet Gastroenterol Hepatol 9:664\u2013676. https:\/\/doi.org\/10.1016\/S2468-1253(23)00479-X","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"11379_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2024.101490","volume":"7","author":"R Mariam Raju","year":"2024","unstructured":"Mariam Raju R et al (2024) EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: a critical review. Results Chem 7:101490. https:\/\/doi.org\/10.1016\/j.rechem.2024.101490","journal-title":"Results Chem"},{"key":"11379_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100863","volume":"64","author":"J Vaquero","year":"2022","unstructured":"Vaquero J et al (2022) Genetic alterations shaping tumor response to anti-EGFR therapies. Drug Resist Updat 64:100863. https:\/\/doi.org\/10.1016\/j.drup.2022.100863","journal-title":"Drug Resist Updat"},{"key":"11379_CR107","doi-asserted-by":"publisher","first-page":"S875","DOI":"10.1016\/j.jtho.2021.08.085","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge DR et al (2021) OA15.04 telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-met+ advanced non-small cell lung cancer. J Thorac Oncol 16:S875. https:\/\/doi.org\/10.1016\/j.jtho.2021.08.085","journal-title":"J Thorac Oncol"},{"key":"11379_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108448","volume":"201","author":"W Choi","year":"2025","unstructured":"Choi W et al (2025) Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma. Lung Cancer 201:108448. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108448","journal-title":"Lung Cancer"},{"key":"11379_CR109","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/annonc\/mdy424.063","volume":"29","author":"SS Ramalingam","year":"2018","unstructured":"Ramalingam SS et al (2018) LBA50-Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol 29:740. https:\/\/doi.org\/10.1093\/annonc\/mdy424.063","journal-title":"Ann Oncol"},{"key":"11379_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2025.116883","volume":"262","author":"X Xia","year":"2025","unstructured":"Xia X et al (2025) Simultaneous determination of four PDE5 inhibitors and metabolites in rat plasma by UPLC-MS\/MS. J Pharm Biomed Anal 262:116883. https:\/\/doi.org\/10.1016\/j.jpba.2025.116883","journal-title":"J Pharm Biomed Anal"},{"key":"11379_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116710","volume":"175","author":"W Huang","year":"2024","unstructured":"Huang W et al (2024) Pde5 inhibition mitigates heart failure in hyperlipidemia. Biomed Pharmacother 175:116710. https:\/\/doi.org\/10.1016\/j.biopha.2024.116710","journal-title":"Biomed Pharmacother"},{"key":"11379_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2020.111311","volume":"190","author":"V Cesarini","year":"2020","unstructured":"Cesarini V et al (2020) Type 5 phosphodiesterase (PDE5) and the vascular tree: from embryogenesis to aging and disease. Mech Ageing Dev 190:111311. https:\/\/doi.org\/10.1016\/j.mad.2020.111311","journal-title":"Mech Ageing Dev"},{"key":"11379_CR113","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1111\/jth.15844","volume":"20","author":"A Degjoni","year":"2022","unstructured":"Degjoni A et al (2022) The NO\/cGMP\/PKG pathway in platelets: the therapeutic potential of PDE5 inhibitors in platelet disorders. J Thromb Haemost 20:2465\u20132474. https:\/\/doi.org\/10.1111\/jth.15844","journal-title":"J Thromb Haemost"},{"key":"11379_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111128","volume":"134","author":"WS Ahmed","year":"2021","unstructured":"Ahmed WS et al (2021) Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors. Biomed Pharmacother 134:111128. https:\/\/doi.org\/10.1016\/j.biopha.2020.111128","journal-title":"Biomed Pharmacother"},{"key":"11379_CR115","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1002\/jcb.24147","volume":"113","author":"X Zhang","year":"2012","unstructured":"Zhang X et al (2012) PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells. J Cell Biochem 113:2738\u20132743. https:\/\/doi.org\/10.1002\/jcb.24147","journal-title":"J Cell Biochem"},{"key":"11379_CR116","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2174\/156802607779941198","volume":"7","author":"B Zhu","year":"2007","unstructured":"Zhu B, Strada SJ (2007) The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary\/cardiovascular vessels. Curr Top Med Chem 7:437\u2013454. https:\/\/doi.org\/10.2174\/156802607779941198","journal-title":"Curr Top Med Chem"},{"key":"11379_CR117","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","volume":"147","author":"A Dasetal","year":"2015","unstructured":"Dasetal A (2015) PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther 147:12\u201321. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.10.003","journal-title":"Pharmacol Ther"},{"key":"11379_CR118","first-page":"3961","volume":"61","author":"GA Piazza","year":"2001","unstructured":"Piazza GA et al (2001) Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Can Res 61:3961\u20133968","journal-title":"Can Res"},{"key":"11379_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103664","volume":"97","author":"G Klejborowska","year":"2020","unstructured":"Klejborowska G, Urbaniak A, Maj E, Preto J, Moshari M, Wietrzyk J, Tuszynski JA, Chambers TC, Huczy\u0144ski A (2020) Synthesis, biological evaluation and molecular docking studies of new amides of 4-chlorothiocolchicine as anticancer agents. Bioorg Chem 97:103664. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103664","journal-title":"Bioorg Chem"},{"key":"11379_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.102997","volume":"89","author":"HA Abou-Zied","year":"2019","unstructured":"Abou-Zied HA, Youssif BGM, Mohamed MFA, Hayallah AM, Abdel-Aziz M (2019) EGFR inhibitors and apoptotic inducers: design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules. Bioorg Chem 89:102997. https:\/\/doi.org\/10.1016\/j.bioorg.2019.102997","journal-title":"Bioorg Chem"},{"key":"11379_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104352","volume":"105","author":"TS Ibrahim","year":"2020","unstructured":"Ibrahim TS et al (2020) Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy. Bioorg Chem 105:104352. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104352","journal-title":"Bioorg Chem"},{"key":"11379_CR122","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cca.2015.01.039","volume":"444","author":"MG Denis","year":"2015","unstructured":"Denis MG et al (2015) EGFR T790M resistance mutation in non small-cell lung carcinoma. Clin Chim Acta 444:81\u201385. https:\/\/doi.org\/10.1016\/j.cca.2015.01.039","journal-title":"Clin Chim Acta"},{"key":"11379_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2025.142326","volume":"1339","author":"VG Deshmukh","year":"2025","unstructured":"Deshmukh VG et al (2025) EGFR inhibitors across generations: progress, challenges, and future directions. J Mol Struct 1339:142326. https:\/\/doi.org\/10.1016\/j.molstruc.2025.142326","journal-title":"J Mol Struct"},{"key":"11379_CR124","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1073\/pnas.0709662105","volume":"105","author":"C-H Yun","year":"2008","unstructured":"Yun C-H et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105:2070\u20132075. https:\/\/doi.org\/10.1073\/pnas.0709662105","journal-title":"Proc Natl Acad Sci USA"},{"key":"11379_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2025.118146","volume":"123","author":"CS Gawli","year":"2025","unstructured":"Gawli CS et al (2025) A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Bioorg Med Chem 123:118146. https:\/\/doi.org\/10.1016\/j.bmc.2025.118146","journal-title":"Bioorg Med Chem"},{"key":"11379_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115471","volume":"222","author":"M Pizzamiglio","year":"2025","unstructured":"Pizzamiglio M et al (2025) Advances and challenges in targeted therapies for HER2-amplified colorectal cancer. Eur J Cancer 222:115471. https:\/\/doi.org\/10.1016\/j.ejca.2025.115471","journal-title":"Eur J Cancer"},{"key":"11379_CR127","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","volume":"2","author":"K Takezawa","year":"2012","unstructured":"Takezawa K et al (2012) Her2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR<SUP>T790M<\/SUP> mutation. Cancer Discov 2:922\u2013933. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0108","journal-title":"Cancer Discov"},{"key":"11379_CR128","doi-asserted-by":"publisher","first-page":"7725","DOI":"10.1021\/acs.jmedchem.7b00515","volume":"60","author":"J Engel","year":"2017","unstructured":"Engel J et al (2017) Structure-guided development of covalent and mutant-selective pyrazolopyrimidines to target T790M drug resistance in epidermal growth factor receptor. J Med Chem 60:7725\u20137744. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00515","journal-title":"J Med Chem"},{"key":"11379_CR129","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ygyno.2025.03.011","volume":"195","author":"EK Lee","year":"2025","unstructured":"Lee EK, Kolin DL, Matulonis UA et al (2025) Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers. Gynecol Oncol 195:152\u2013164. https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.011","journal-title":"Gynecol Oncol"},{"key":"11379_CR130","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-022-01311-6","volume":"15","author":"K Shi","year":"2022","unstructured":"Shi K et al (2022) Emerging strategies to overcome resistance to third-generation EGFR inhibitors. J Hematol Oncol 15:94. https:\/\/doi.org\/10.1186\/s13045-022-01311-6","journal-title":"J Hematol Oncol"},{"key":"11379_CR131","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang Y et al (2022) Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther 7:329. https:\/\/doi.org\/10.1038\/s41392-022-01168-8","journal-title":"Signal Transduct Target Ther"},{"key":"11379_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2019.109497","volume":"67","author":"MI Parker","year":"2020","unstructured":"Parker MI et al (2020) Proliferative signaling by ERBB proteins and RAF\/MEK\/ERK effectors in polycystic kidney disease. Cell Signal 67:109497. https:\/\/doi.org\/10.1016\/j.cellsig.2019.109497","journal-title":"Cell Signal"},{"key":"11379_CR133","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","volume":"139","author":"R Roskoski","year":"2019","unstructured":"Roskoski R (2019) Small molecule inhibitors targeting the EGFR\/ErbB family of protein tyrosine kinases in human cancers. Pharmacol Res 139:395\u2013411. https:\/\/doi.org\/10.1016\/j.phrs.2018.11.014","journal-title":"Pharmacol Res"},{"key":"11379_CR134","doi-asserted-by":"publisher","first-page":"2505e2513","DOI":"10.1007\/s00044-014-1315-3","volume":"24","author":"H Irannejad","year":"2015","unstructured":"Irannejad H et al (2015) Anticonvulsant activity of 1,2,4-triazine derivatives with pyridyl side chain: synthesis, biological, and computational study. Med Chem Res 24:2505e2513. https:\/\/doi.org\/10.1007\/s00044-014-1315-3","journal-title":"Med Chem Res"},{"key":"11379_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ardp.201400045","volume":"347","author":"M Amir","year":"2014","unstructured":"Amir M, Ali I, Hassan MZ, Mulakayala N (2014) Design, synthesis, and biological evaluation of hydrazine incorporated 1,2,4-triazines as anticonvulsant agents. Arch Pharm Chem Life Sci 347:1\u201311. https:\/\/doi.org\/10.1002\/ardp.201400045","journal-title":"Arch Pharm Chem Life Sci"},{"key":"11379_CR136","doi-asserted-by":"publisher","first-page":"29e36","DOI":"10.1016\/0920-1211(92)90088-B","volume":"1","author":"DS Danny","year":"1992","unstructured":"Danny DS, Rene HL, Jill LS, Alan V (1992) Comparative anticonvulsant potency and pharmacokinetics of (+)- and (-)-enantiomers of stiripentol. Epilepsy Res 1:29e36. https:\/\/doi.org\/10.1016\/0920-1211(92)90088-B","journal-title":"Epilepsy Res"},{"key":"11379_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.102978","author":"JN Philoppes","year":"2019","unstructured":"Philoppes JN, Lamie PF (2019) Design and synthesis of new benzoxazole\/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents. Bioorg Chem. https:\/\/doi.org\/10.1016\/j.bioorg.2019.102978","journal-title":"Bioorg Chem"},{"key":"11379_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113222","author":"PF Lamie","year":"2021","unstructured":"Lamie PF, Philoppes JN et al (2021) Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M\/HER2 inhibitors: design, synthesis, structureeactivity relationship and biological activity as potential antitumor and anticonvulsant agents. Eur J Med Chem. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113222","journal-title":"Eur J Med Chem"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11379-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:02:12Z","timestamp":1791180132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11379-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":138,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11379"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11379-0","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}